BENEVOLENTAI financials
BENEVOLENTAI
2221003P54KEDC3P4Z33 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | £7.3M | £10.6M |
| Other income | £423.0K | £166.0K |
| Administrative expenses | £24.6M | £135.9M |
| Operating profit (EBIT) | -£77.6M | -£197.0M |
| Finance costs | £407.0K | £2.1M |
| Profit before tax | -£72.7M | -£179.9M |
| Income tax expense | -£9.3M | -£15.9M |
| Profit for the year | -£63.3M | -£163.9M |
| Total comprehensive income | -£63.3M | -£163.9M |
| Per share | ||
| Basic EPS | £-53.50 | £-150.20 |
| Diluted EPS | £-53.50 | £-150.20 |
| Free cash flow / share | £-0.49 | £-0.72 |
| Cash flow statement | ||
| Net cash from operating activities | -£57.1M | -£76.9M |
| Net cash from investing activities | £7.9M | -£41.4M |
| Purchase of PP&E (capex) | £1.1M | £1.2M |
| Net cash from financing activities | -£2.1M | £163.0M |
| Net change in cash | -£51.3M | £44.7M |
| Balance sheet | ||
| Total assets | £123.8M | £186.0M |
| Non-current assets | £32.4M | £33.9M |
| Property, plant & equipment | £2.3M | £2.6M |
| Right-of-use assets | £4.6M | £5.9M |
| Intangible assets & goodwill | £23.5M | £23.5M |
| Current assets | £91.4M | £152.1M |
| Trade & other receivables | £8.7M | £5.8M |
| Cash & equivalents | £36.5M | £88.4M |
| Total equity | £94.3M | £154.0M |
| Non-current liabilities | £4.5M | £6.3M |
| Lease liabilities (non-current) | £3.8M | £5.7M |
| Current liabilities | £25.0M | £25.6M |
| Lease liabilities (current) | £925.0K | £1.7M |
| Trade & other payables | £10.4M | £14.9M |
| Derived metrics | ||
| Free cash flow | -£58.2M | -£78.1M |
| Operating margin | -1058.2% | -1865.9% |
| Net margin | -863.7% | -1552.3% |
| Return on equity | -67.2% | -106.4% |
| Cash conversion ratio | 0.90× | 0.47× |
| Capex coverage | -51.70× | -66.42× |
| Other reported items | ||
| Adjusted Weighted Average Shares | 118.3M | 109.1M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -£3.1M | -£1.5M |
| Adjustments For Depreciation and Amortisation Expense | £2.9M | £3.1M |
| Adjustments For Finance Costs | £407.0K | £2.1M |
| Adjustments For Finance Income | £5.3M | £19.3M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -£5.0K | -£2.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | £4.2M | -£1.5M |
| Adjustments For Provisions | -£3.6M | -£6.2M |
| Adjustments For Sharebased Payments | £5.7M | £33.8M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | £669.0K | -£3.1M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -£54.6M | -£67.8M |
| Current Deferred Income Including Current Contract Liabilities | £11.6M | £2.9M |
| Current Provisions | £2.2M | £5.9M |
| Current Tax Assets | £9.8M | £16.1M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£632.0K | £3.2M |
| Finance Income | £5.3M | £19.3M |
| Income Taxes Paid Refund Classified As Operating Activities | -£16.1M | -£12.2M |
| Increase Decrease Through Sharebased Payment Transactions | £5.7M | £33.8M |
| Increase Decrease Through Transactions With Owners | £3.6M | £256.9M |
| Intangible Assets Other Than Goodwill | £19.0K | £20.0K |
| Interest Paid Classified As Financing Activities | £81.0K | £122.0K |
| Interest Received Classified As Investing Activities | £3.7M | £1.5M |
| Issued Capital | £103.0K | £100.0K |
| Liabilities | £29.6M | £32.0M |
| Merger Reserve | -£524.6M | -£524.6M |
| Net Assets Liabilities | £94.3M | £154.0M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | £1.9M | £1.9M |
| Noncurrent Provisions | £700.0K | £626.0K |
| Noncurrent Receivables | £171.0K | £0 |
| Other Adjustments For Noncash Items | £0 | £83.1M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | £37.0K | £31.0K |
| Other Comprehensive Income Net of Tax Hedges of Net Investments In Foreign Operations | £37.0K | £31.0K |
| Payments For Share Issue Costs | £0 | £11.3M |
| Proceeds From Issuing Other Equity Instruments | £0 | £136.7M |
| Recoverable Amount of Asset Or Cashgenerating Unit | £12.2M | — |
| Research and Development Expense | £60.8M | £71.9M |
| Reserve of Exchange Differences On Translation | £365.0K | £328.0K |
| Reserve of Sharebased Payments | £161.0M | £203.7M |
| Retained Earnings | -£519.4M | -£456.1M |
| Share Premium | £976.8M | £930.5M |
| Shortterm Deposits Classified As Cash Equivalents | £36.4M | £41.7M |
| Warrant Liability | £2.0K | £352.0K |
| Weighted Average Shares | 118.3M | 109.1M |
Every line item above is a fact tagged in BENEVOLENTAI's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.